RG 7624

Drug Profile

RG 7624

Alternative Names: MCAF-5352A; NI-1401; NI-1401/α-IL-17; RG-7624

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator NovImmune SA
  • Developer Genentech
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation
  • Discontinued Autoimmune disorders

Most Recent Events

  • 05 Sep 2016 Phase-I clinical trials in Inflammation in USA (Unspecified) before September 2016
  • 28 Jan 2015 Discontinued - Phase-I for Autoimmune disorders (In volunteers) in Canada (SC)
  • 12 Mar 2013 Genentech completes a phase Ib trial in Autoimmune disorders (in volunteers) in Canada (NCT01540760)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top